AI Article Synopsis
- Developing new cancer therapies requires a deep understanding of how the immune system responds to treatments.
- The ELISpot assay is a quick method that detects individual T cells producing cytokines, specifically focusing on measuring activated CD8 T cells that produce interferon gamma (IFN-γ).
- The protocol uses splenocytes from tumor-afflicted mice after radiation therapy, allowing researchers to study the behavior and characteristics of these specific immune cells in response to tumor-derived peptides.
Article Abstract
To develop new effective therapeutic strategies for cancer patients, there is a need for extensive and precise insights into the mechanisms involved in the immune response to anti-cancer treatments. The enzyme-linked immunospot (ELISpot) assay is a rapid and reproducible technique that allows the detection of cytokine-producing antigen-specific T cells at the single cell level. This protocol describes an interferon gamma (IFN-γ) ELISpot method for measuring antigen-specific murine CD8 T cells that produce IFN-γ, a marker of their activation and cytotoxicity. Splenocytes from tumor-bearing mice treated with radiation therapy were used as source of CD8 T cells and were stimulated with a tumor-derived peptide. This method was facilitated by a ready-to-use assay kit and provides a tool to analyze the specificity, intensity, and kinetics of specific CD8 T cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.mcb.2024.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!